INDEX

Volume Three January through December 1969 DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages 1 - 32	July	Pages 181 - 208
February	Pages 33 - 64	August	Pages 209 - 232
March	Pages 65 - 92	September	Pages 233 - 264
April	Pages 93 - 124	October	Pages 265 - 296
May	Pages 125 - 152	November	Pages 297 - 336
June	Pages 153 - 180	December	Pages 337 - 376

42-548, anorexigenic activity, 230

AAMC, see Association of American Medical Abnormalities, in response to drugs, 14 Absorption rate, see Drug absorption AC 3092, toxicology, 293 ACATA and deferrioxamine B, in primary hemochromatosis, 291 Acetaminophen, oral potentiation by anticoag-ulants, 62 Acetazolamide, effect on acute mountain sickess, 178 N-Acetyl-p-aminophenol, see Acetaminophen Achilles reflex, and antipsychotic drugs, 121 ACTH, see Corticotropin Administration Routes of Parenteral Injections, 42; see also Letters, 127 Adriamycin, antitumor antibiotic, 364 Adverse drug reactions see also Drug interactions abstracts, 31, 91, 150, 206, 262, 292, 333, monitoring in patients, 115

parameter in physiological response to drugs, effect of heparin in relation to, 91

Adverse non-drug reactions, 91

Agedal, see Noxiptilin AHA, see American Hospital Association Alcohol, see Ethanol

Aldosterone, suppression by heparin, 179 Alexander, W. E. (co-author), A Drug Usage Study, 6; Part II, 303

Allergic reactions, to tuberculostatic drugs, 31 Allergies, drug, see Adverse drug reactions Allopurinol, urinary xanthines stones following, 150

American Association of Medical Colleges, calls for curriculum changes, 92

American Association of Poison Control Centers, meeting, 152 American Hospital Association, health aide training program, 92

American Pharmaceutical Association, Montreal Convention, 124

Amiloride hydrochloride, potassium-sparing di-

uretic, 88 2-Amino-5-(1-methyl-5-nitro - 2 - imidazolyl)-1,3,4-thiadiazole, antimicrobial activity, 89 Amphetamine poisoning, chlorpromazine, 28

Ampicillin absorption, 59 exacerbation of salmonella enteritis due to,

Angina pectoris imolamine in, 90 propranalol and isosorbide in, 121 verapamil in, 90

Angolon, see Imolamine

Anorexigenic agents fenfluramine, 365 fenfluramine, 365 long-acting, 61 42-548, new, 230

Analgesic abuse, 62

Anthelmintics, interactions, 130

Antibiotics ntibiotics antitumor, 364 bacterial sensitivity to, 231 combinations, 70 interactions, 70 regimens in acute leukemia, 212 resistance, 177 therapeutic incompatibilities, 355

Antibodies, international standards, 100 Anticoagulants, oral potentiation by acetomin-ophen, 62

Antifungal antibiotics, interactions, 70 Antigens, international standards, 100 Antihemophilic Factor Method Four, 158

Anti-infective agents efficacy, 312 interactions, 70

Anti-inflammatory agents, effect masked by aspirin, 30 Antineoplastics, interactions, 196

Antipsychotic drugs, and achilles reflex, 121 Antithyroids, single dose, 290

Antituberculars, interactions, 130 Antitumor antibiotic, 364

Antivirals, effectiveness of chlorine bleach, Appetite suppressant, 230

Archambault, George F., receives Remington Award, 180

Arsenic intoxication, fatal transplacental 149 Ap 752, see 2-(2-Methoxy-ethoxy)-5-acetaminoacetophenone Arvin, in priapism, 120

Aspirin

spirin gastrointestinal loss, 365 interaction with nonsteroidal drugs, 30 intravenous, 331 physiological availability, 278

Association of Military Surgeons, meeting, 64 Atropine, hyperreactivity in Down's syndrome,

DEC 69

Azalomycin F, antibiotic, 121 Azathioprine, 158

B

Bacteria, drug resistance of, 177 Bacterial endocarditis, cephalothin in, 149 Bacterial sensitivity, to antibiotics, 231 Bactericidal agents, interactions, 70 Bacteriostatic agents, interactions, 70 Barbital, teratogencity, in mice, 332 BAY 1521, see Noxiptilin Benfante, Paule, (co-author), Screening for Py-rogens in Injectable Solutions by Means of Millipore Filters, 286

Benya, Theodore J. (author), Responsibility for Transcription of Medication Orders, (edit.), 37

2-Benzolsulfor nide-5-methoxypyrimidine, see Glycodiazine

Berman, Alex (author), Drug Testing and the Public Welfare, (edit.), 269 Berry, Charles C. (co-author), Misuse of Pre-scription Medications by Outpatients, 270

Biological half-life, see Half-life, biological Biological standards, 100 Biologicals, new, 158

Biologicals, new, 158
Biopharmaceutics
see also Pharmacokinetics
disintegration of dosage forms in vitro and
in vivo, Part I, 198; Part II, 224; Part
III, 278; Part IV, 324; Part V, 357
pharmacokinetic concepts for the clinician,
pharmacist and nurse, 108
relationship between dosage forms, dosage
regimens and pharmacokinetics, 21
relationships among form of drug, dosage
form, routes of administration and concentration curves and urinary excretion

centration curves and urinary excretion curves, 170

Bjerke, Paul, honored, 92

Blutene, see Toluidine blue Body weight, as parameter in response to drugs, 14

drugs, 14

Book Reviews
Antimicrobial Agents, 151
Calculations in Pharmacy, 57
Cell Physiology and Pharmacology, 334
Clinical Pharmacology, 57
Clinical Toxicology of Commercial Products.
Acute Poisoning, 294
Cure for Cancer—A National Goal, 56
Drug Responses in Man, 333
Elsevier's Dictionary of Pharmaceutical Science and Technology, Vol 1, 294
Handbook of Non-Prescription Drugs, 57
Index Des Travaux D'Histoire De La Phar-

macie (1913-1963). I-Evolution De La Pharmacie Et Du Pharmacien A La Lumiére Des Noms Qu'ils Ont, 151 he Intercantonal Agreement for the Con-trol of Drugs of June 16, 1954, 334 n Introduction to the Study of Disease, 208
Medical Plans and Health Care, 56
The Merck Index. Eighth Edition, 56
Merck Veterinary Manual, 207
Pharmaceutical Calculations, 57
Pharmaceutics, Galenical Pharmacy, 334
Pharmacological Principles and Practice, 208
Principles of Pharmaceutical Marketing, 151
Review of Medical Pharmacology, 335
Safer and More Effective Drugs, 294
State Licensing of Health Occupations, 294
Sterilization and Disinfection, 207
The Third World of Medicine, 208

Bouchard, Vincent (author), Toward a Clinical Practice of Pharmacy, 342 Briner, William H., receives award, 152

Bu-310, anti-inflammatory activity, 29 Burkholder, David (author), The Pharmacists' Communications in Drug Related Patient Care. (edit.), 69

Burkholder, David (co-author), A Collabora-tive Hospital Program for Clinical Teach-ing, 38

Burns, early treatment, 28

Butaperazine, evaluation in schizophrenic pa-tients, 123

Butaperazine (Repoise - Robins), 158

C

Canada, Andrew T., Jr., (co-author), The Use of A Pharmacist in Obtaining Medication Histories, 115

Carbamazephine (Tegretol - Geigy), 158 Carbenicillin, in severe infections, 231

Carbon tetrachloride in household products, banned by FDA, 64 poisoning, 367

Carica papaya, effect on edema and ecchymosis, 231

Carisoprodol toxicity, 333

ase, Robert (co-author) A Collaborative Hospital Program for Clinical Teaching, 38 Cephalexin, evaluation, 290

Cephaloridine and cephalothin, comparative pharmacodynamics in chronic uremia, 148

Cephaloridine (Loridine - Lilly), 158 Cephalosporin, see Cephalexin

Cephalothin (Keflin - Lilly), 158; in bacterial endocarditis, 149

Cephalothin and Cephaloridine, comparative pharmacodynamics in chronic uremia, 148 Cerebral arteriography, Thorotrast in, 59

Chemical mace, see Mace

Chlordiazepoxide therapy, neurological disor-order, 333

Chlorine bleach, antiviral effectiveness, 149 Chloramphenicol preparations, absorption, 29 7-Chloro-7-Desoxylincomycin, see Sobelin

N-4[2-(Chloro - 2 - methoxybenzamide)ethyl]-phenylsulfonyl-N'-cyclohexylcarbamide, see HB 419

4-Chlorophenyl - 3-4 - dichlorobenzole sulfam-

ide, see Reseptyl-urea N-(3-Chloropropyl) - 1 - methyl - 2 - phenyl-ethylamine hydrochloride, 230

Chlorpromazine in amphetamine poisoning, 28 liver damage from, 31

Cholesterol analysis, performance of "Kits" used for, 149

Clinical conferences, pharmacy, 342

Clinical history, 115; see also Drug Profiles Clinical pharmacy, 38, 115, 157, 218, 322, 342, 348

Clinician, medical, pharmacokinetic concepts in drug usage, 108

acute muscular syndrome associ-Clofibrate, ated with, 91 1-Chloroacetophenone, contact dermatitis from, 292

Chlorpropamide accumulation caused by dicumarol, 179 plasma insulin and glucose response to, 90 Colchicine, vitamin B-12 malabsorption in patients receiving, 91 Colistimethate, toxicity, 120

Coly-mycin injection, see Colistimethate Combinations, drug, 312

Compound N-1113, vasodilator effect, 332 Computer applications, in hospital pharmacy,

Continelli, Basil (co-author), A Collaborative Hospital Program for Clinical Teaching, 38 Continuing Education, see Education, pharmacy, continuing

Coombs' test, positively induced by drugs, 31 Corneal anesthetics, keratitis from misuse, 91 Corticosteroids, efficacy, 312

Corticotropin, efficacy, 312

Coumarin metabolism, by intestinal microflora in rats, 177

Cuprophane membrane, diffusion of drugs through, 186

Cyclamate, toxicity, 293 Cyproheptadine (MSD), 158

D

DA1686, pharmacology, 59

Dactinomycin, for Wilm's tumor, 179

Daunomycin, (Farmitalia, Italy), 158; and prednisone in leukemia, 123
Davis, Arthur J. (co-author), Diffusion of Drugs Through the Cuprophane Membrane, 186

Debrisoquin sulfate, clinical evaluation, 121 Deferoxamine (Desferal - Ciba), 158

Deferrioxamine B and ACATA, in hemochro-matosis, 291

de Haen, Paul, (author), New Products Parade, 1968. 158

Dermatology, HS 592 in, 61 Dermatitis, from 1-chloroacetophenone, 292

Desferal, see Deferoxamine Dexamethasone, suppression test, 179 DIA, see Drug Information Association

Dialyzing units, cleaning and storage, 120 Dichlorphenylaminoimidazoline, hypotensive effect, 332 intravenous. Dicoumarol, cause of chlorpropamide accumu-

lation, 179 Digoxin intoxication, sensitivity to propranolol after, 90

3,4-Dihydro - 2(1H)-isoquinolinecarboxamidine sulfate, see Debrisoquin sulfate

Dihydrostreptomycin, efficacy, 312 Dilantin, see Diphenylhydantoin

5-(Dimethylaminoethyloxyimino) - 5H-diben [a,d] cyclohepta-1,4-diene, see Noxiptilin 5H-dibenzo

4-(3-Dimethylamino-propyliden) - 9,10 - dihydro-4H-benzo (4,5) cyclohepta (1,2-b) thiophene, see IB-503

Dimethyl sulfoxide, antimicrobial activity, 88 1,5-Dimorpholino - 3 - (1-naphthyl) - pentane (DA-1686), 59

phenylhydantoin, metabolism inhibited by phenyramidol, 30 Diphenylhydantoin,

3-(Diphenylmethoxy) - 8 - isopropylnortropan methane-sulfonate, see Sch 221

Disintegration test media, 224 Disintegrating agents, 357

Disintegration time, 224, 278, 357

Disodium carboxybenzylpenicillin, 231 Dissolution rate, dosage form, 198, 278

Diurnal variation, as parameter in physiological response to drugs, 14

DMSO, see Dimethyl sulfoxide Doctor of Pharmacy, program at Cincinnati, 368

Dosage forms, biopharmaceutics of, 21, 158, 170, 198, 224, 278, 287, 357

Dosage formulation, in protected environ-ments, 212

Dosage regimen, drug, 21 Dose response, drug, 108

Dose-response plots, drug, 82

Down's syndrome, hyperreactivity to atropine in, 91

Dropropizine, antitussive activity, 331 Drug absorption, 21, 82, 198, 278

Drug abuse, 367 Drug action, physiological response, 14

Drug Actions, Interactions and Reactions, 28, 58, 88, 120, 148, 177, 204, 230, 260, 290, 331, 364

Drug administration instructing pharmacists, 342 oral, 170 parenteral, 55, 170 time, factor in drug response, 14

Drug allergies, see Adverse drug reactions Drug antagonism, 70; see also Drug interactions

Drug Combinations, therapeutic incompatibilities, 355; see also Drug interactions Drug communications, 69, 218; see also Drug

information Drug compendia, 158

Drug distribution systems, see Hospital medi-

Drug dosage, in patients undergoing hemo-dialysis, 186

Drug efficacy study, 158, 237, 269, 312 Drug elimination, 21

Drug excretion, 170

Drug formulation, 287, see also Biopharmaceutics

Drug histories, see Drug profiles

Drug hypersensitivity, see Adverse drug reactions

Drug identification, 5, 115

Drug information, 38, 69, 115, 348, 368

Drug Information, 38, 69, 113, 348, 300

Drug Information Association

Fifth Annual Meeting, 32

symposium on drug information for the medical profession—interval from source to user, 368

symposium on formulation factors affecting the therapeutic performance of drug products, 32, 287

Drug Intelligence and Clinical Pharmacy (edit.), 158 European Study Mission, 64, 176

Drug Interactions rug interactions abstracts, 30, 62, 123, 179, 205, 292, 363 anthelmintics. 130 antibiotics, 70, 355 anti-infective agents, part 1, 70; part 2,

130 antineoplastic agents, 196 antitubercular agents, 130 compilation, 365 plasmodicides, 130 problems of, 158 sulfonamides, 130

Drug labeling, 5

brug metabolism biopharmaceutics, 21 by intestinal microflora, 177 of salicylamide, 170 pharmacokinetics, 82

Drug profiles, 38, 115, 342, 348

Drug resistance 177

Drug synergism, 70; see also Drug interactions Drug synthesis, 158

Drug tolerance, as factor in response to drugs, 14

Drug usage, see Drug utilization Drug Usage Study, 6; Part II, 303

Drug utilization, 6, 304

Drugs, (generic and proprietary names), 158 Drugs, investigational, 158

Drugs, new, 158

Drugstores, and pharmacies, (edit.), 185 Dunphy, Thomas (co-author), A Collaborative Hospital Program for Clinical Teaching, 38 Dynapen, see Sodium dicloxacillin monohy-drate

E

Editorials Continuing Education at Cincinnati in July,

Continuing Education at Cincinnati in July, 97
Drug Intelligence and Clinical Pharmacy, 158
Drug Testing and the Public Welfare Ethics of Human Experimentation, 303
Everything Counts in the Long Run, 129
An Example of Physician-Pharmacist Cooperation, 211
Origins and Scope of the Drug Efficacy Study, 237
Packaging and Labeling of Prescription Drugs, 5
Pharmacy's Directions. 1. Pharmacies and Drugstores, 185
The Pharmacist's Communications in Drug Related Patient Care, 69
Practitioners as Teachers, 341
Responsibility for Transcription of Medication Orders, 37

EDPE, see Electronic data processing equip-Education clinical pharmacy, 218, 322, 348 continuing, in pharmacy, 91, 92, 97 hospital pharmacy, 39 Elderly, physiological response to drugs, 14 EMPT, see Fenfluramine Enteric coatings, ingredients, 278 Equilibrium state, drug dosage, 108 Erythromycin activity in alkaline medium, 89 hepatitis from, 367 Ethacrynic acid compared with mercaptomerin in acute pul-monary edema, 59 pharmacology, 28 Ethanol, toxicity to liver, 178

Europe, new drugs, 1968, 158

European Hospital Pharmacy Study Mission, 63, 176

Ethics, of human experimentation, 303

Ethionamide, liver toxicity, 293

FDA, see Food and Drug Administration Fenfluramine, anorexigenic activity, 365 Fentanyl (Sublimaze - McNeil), 158 FIP, see International Pharmaceutical Federation Folic acid and hemodialysis, hemostasis of, 149 Formulation Factors Affecting the Therapeu-tic Performance of Drug Products, 287 Food and Drug Administration
Drug Efficacy Study, 158, 237, 269, 312
Task Force on Prescription Drugs, 5 Francke, Don E. (author), edit., 5, 97, 157, 185, 211, 237, 341 Francke, Gloria N. (author), Evolvement of Clinical Pharmacist, 348 Frazier, Walter M. (author), Administration Routes of Parenteral Injections, 42 Fixed combinations, drug, 158, 312 Furazolidone, MAO inhibitor, 29 Furosemide, pharmacology, 28 Furoxone, see Furazolidone

G

N-Gamma-dimethylaminopropyl-l, 2 - benzi-sothiazolone, anti-inflammatory activity, 29 Garamycin, see Gentamicin Gastrointestinal gas, treatment, 30 Gentamicin antibacterial activity, 290 properties, 59 Glafenine (Roussel - Uclaf, France), 158 Glucagon, cardiovascular effects, 28 Glycodiazine, simulated biodynamics of, 120 Godley, Leo F., receives 1969 H. A. K. Whitney Lecture Award, 63

Half-life, biological, defined, 21, 108

Haller, Robert E., dies, 128 Hallucinations, with pentazocine, 333 Halothane, hepatitis from, 91, 150 Halothane, hepatitis from, 91, 150
Hartshorn, Edward A. (author)
Drug Interactions. III. Classes of Drugs
and Their Interactions, Part I. Anti-Infective Agents, 70; Part 2, 130
Drug Interactions. Antineoplastics, 196
Physiological States Altering Response to
Drugs, 14
Harvey A. K. Whitney Award, 1969, 63
HB 419, oral diabetic, 364
Haath adde training program, 92 Health aide training program, 92 Hemodialysis, diffusion of drugs through cuprophane membrane, 186 Heparin cause of aldosterone suppression, 179 effect in relation to sex and age, 91 Hepatitis, attributable to halothane 91, 150 History, hospital pharmacy, 348 Homeostasis, of folic acid and hemodialysis,

Hormones, vitamins and enzymes, international standards, 100 Hospital medication systems, 6, 37, 39, 304, 322, 342 House dust extract, prolonged action prepara-tion, 60 HS 592, in dermatology, 61 Human experimentation, ethics of, 303 Humenchuk, R. J. (co-author), A Drug Usage Study, 6; Part II, 303 Hydrea, see Hydroxyurea Hydrochloric acid, effect on iron absorption, Hydrochlorothiazide, physiological availability, 6-Hydroxy-1,3-benzoxathiol-2-one, see Tioxo-5-Hydroxy-5-p-chlorophenyl, - 2,3 - dihydro-5-H-imidazo(2,1-a) isoindole, 230 Hydroxyurea (Hydrea - Squibb), 158 Hyperinsulinism, in infants with erythro-blastosis, 29 Hypersensitivity, drug, monitoring in patients, 115; see also Adverse drug reactions Hypoglycemia and hyperinsulinism in infants with erythroblastosis fetalis, 29

ID-955, synthesis and pharmacology, 291

IB-503, tranquilizing activity, 231

INH, see Isoniazid

Imipramine and melitracen, compared in de-pressed patients, 230 Immune Serum Globulin, (RhoGAM - Ortho), Imolamine, in anginal syndrome, 90 Imuran, see Azathioprine Inderal, see Propranolol Indomethacin, interaction with aspirin, 30 Infants and newborn, physiological response to drugs, 14 Injections, administration, 42, 170 Insulin, tolbutamide with hypoglycemic shock, Interactions, see Drug interactions International biological standards, 100 International Conference on Hospital and In-stitutional Pharmacy (Montreal), 124 International Pharmaceutical Federation, 1971 meeting in Washington, 92 Interprofessional cooperation, 211 Intestinal fluid loss, reduction, 30 Intravenous infusion, constant rate, 170 Intravenous aspirin, 331 Intravenous dichlorphenylaminoimidazoline, hy-potensive effect, 332 Intravenous solutions routes of administration, 42 screening for pyrogens, 296 Investigational drugs

One also Drug Actions, Interactions and Adverse Reactions index of codes to, 335 research, 158 Iowa Hospital Pharmacy Seminar, 32 Iprindole, (Wyeth), 158 Iron absorption, effect of hydrochloric acid on, 89 Irrigor, see Imolamine Isoniazid, allergic reaction to, 31 Isoproterenol (Isuprel - Winthrop), 158 Isosorbide dinitrate, in angina pectoris, 121 Isuprel, see Isoproterenol

Johnson, Charles M., honored, 92

Keeping, D. (co-author), A Drug Usage Study, 6; Part II, 303 Keflin, see Cephalothin Keratitis, from misuse of corneal anesthetics,

Kiil, flate-plate hemodialyzer, 186 Kowal, Nathan H. (co-author), Diffusion of Drugs Through the Cuprophane Membrane, 186

Labarre, Jules (co-author), Screening for Py-rogens in Injectable Solutions by Means of Millipore Filters, 286

LA 1211, see Imolamine

Labeling, see Drug Labeling Lactose, tablets, disintegration time 357 Laminar air flow, 212 Latiolais, Clifton J. (co-author), Misuse of Pre-scription Medications by Outpatients, 270 Lead poisoning, in the slums, 333 Letters, 127 Leukemia acute therapy, 212 daunomycin and prednisone in, 123 Levallorphan, interaction with meperidine, 366 Lidocaine anti-arrhythmic effect, 290 in acute myocardial infarction, 177 Lincomycin, penetration into cerebrospinal fluid, 148 Literature, 56, 151, 207, 294, 335 Liver damage, from phenothiazine compounds, Lithium, mechanism of action, 122 Loridine, see Cephaloridine LSD, see Lysergic acid diethylamide Lysergic acid diethylamide, syndrome, 58

M Magnesium trisilicate tablets, disintegration Mathematical equations, application to pharmacokinetics, 82, 142 McHale, Mary K. (co-author), The Use of A Pharmacist in Obtaining Medication His-tories, 115 McKinley, James D., Jr. (author), Antibiotic Prophylaxis and Protected Environment as Adjuncts in the Treatment of Acute Leu-kemia, 212 Medical systems, formation of society, 368 Medication errors, 270, 348 Medication histories, see Drug profiles Medication misuse, 270 Medication orders, 6, 37, 39; see also Hos-pital medication systems Medication profiles, see Drug profiles Melitracen and imipramine, compared in de-pressed patients, 230 Mace, chemical, blindness from, 366 Membranes, dialyzing, 186 Menopause, as factor in response to drugs, 14 Meperidine, interaction with levallorphan 366 Mercaptomerin, compared with ethacrynic acid in treatment of pulmonary edema, 59 Mesyldegranol, immunosuppressive action, 61 Methacycline hydrochloride, marketed, 64 1,6-Di(methanesulfonyloxyl-ethylamino) - 1,6-didesoxy-d-mannitol - 2 - hydrochloride, immunosuppressive action, 61 2-(2-Methoxy-ethoxy) - 5 - acetamino-aceto-phenone metabolism and blood levels, 122

1-(3',4'-Methylenedioxybenzoyl) - 2 - methyl-5-methoxy-3-indolylacetic acid, see ID-955 10-Methyl-2-phenothiazinyl acetic acid, see Metiazinic acid Metiazinic acid, pharmacology, 331 Microbial content, of agents with natural or seminatural active ingredients, 88

1-Methyl-3-nitro - 1 - nitrosoguanidine, anti-microbial activity of, 89

Microbiological testing, nonsterile pharmaceuticals, 88, 122 Military Surgeons Association, meeting, 64 Millipore filters, screen for pyrogens, 286

MK 870, see Amiloride hydrochloride

Models
in biopharmaceutics, 108
in pharmacokinetics, 82

MODS, (medication order display system), 6 Monoamine oxidase inhibitors, interaction with phenylpropanolamine, 365

Monosodium glutamate, CNS damage in infants, 366 Motor Vehicle Accidents, medical and related aspects, third triennial congress, 152

Mountain sickness, acute effect of acetazol-amide on, 178

Mycosis fungoides, nitrogen mustard in, 332 Myers, D. Jack, honored, 92

Naftidrofuryl (Oberval Lipa, France), 158

N-1113 see Compound N-1113

Nalidixic acid, interference in urinary 17-ketosteroid determinataion, 149 National Academy of Sciences, National Research Council, Drug Efficacy Study, 158, 237, 312 National Research Council, see National Academy of Sciences New drug applications, (NDA), 158 New drug investigation, 364 News, 32, 63, 92, 124, 152, 180, 263, 368 Nitrofurantoin, effect of renal function on urinary concentration, 90 Nitrogen mustard, in mycosis fungoides, 332 Nitroglycerin, sustained release, 292

Nonsterile pharmaceuticals, microbiological testing, 88, 122 Nonsteroidal drugs, interaction with aspirin, 30 Noxiptilin, new antidepressant, 291 NSC 9369, antimicrobial activity, 89 Nurse, pharmacokinetic concepts in drug usage, 108

Oliver, John A. (author), Everything Counts in the Long Run (edit.), 129 Olszewski, Stephen, elected, 64 Outpatient pharmacy service, 270 Oxyprenalol, in thyrotoxicosis, 58

Pancouronium Bromide, (Organon, England), Para-aminosalicylic acid, allergic reaction to,

Parenteral solutions, routes of administration,

PAS, see Para-Aminosalicylic acid Pathocil, see Sodium dicloxacillin monohydrate

Patient isolators, 212 Patients' charts, utilization by pharmacist, 38 Pediatric therapy, 332

Penicillias
drug inhibiting effect, 70
effect of probenecid on distribution, 60
physiological availability, 278
therapeutic incompatibilities, 355

Pennsylvania Hospital Pharmacy Assembly, 64 Pentazocine (Talwin - Winthrop), 158; hal-lucinations with, 333

Peptic ulcer, from analgesic abuse, 62 Percutaneous mycobacterium test, (PMT), 290 Pharmacist, pharmacokinetic concepts in drug usage, 108

Pharmacist-physician cooperation, 211

Pharmacokinetics see also Biopharmaceutics construction of percent absorbed-time plots based on two compartment open model,

introduction to compartment models, mathematical methods, part two, 142 Pharmacy team concept, 342

Phenothiazines, unusual therapeutic uses, 365 Phenothiazine compounds, liver damage from,

1-Phenyl - 4-(2,3-dihydroxypropyl) - diethylene diamine, 331

3-Phenyl - 4-diethylaminoethyl - 5-imino-1,2,4-oxadiazole hydrochloride, 90 Phenylbutazone, interaction with aspirin, 30

Phenylpropanolamine, interaction with MAO inhibitors, 365 Phenyramidol, inhibition of diphenylhydantoin metabolism, 30

Physician-pharmacist interaction, 211, 322 Physicians' orders, 38

Physiological availability, dosage form, 278, 287; see also Biopharmaceutics Physiological response to drugs, 14

Phytotoxicology, see Poisonous plants 1-Piperidino-3-(4'-octylphenyl) - propane - 3-one, see Compound N-1113

Plasma concentration-time relationships, 21, 82, 108, 170

Plasma, insulin and glucose, response to chlor-propamide therapy, 90

Plasmodicides, interactions, 130 PMT, see Percutaneous mycobacterium test

Poison control center, list of texts, 366 Poisoning, triorthocresylphosphate, 91; lead, 333; plants, 366

Polyene macrolides, effect on prostate gland and canine prostatic hyperplasia, 29 Prednisone and daunomycin, in leukemia, 123 Pregnancy, as factor in response to drugs, 14 Prescription practices, improvement, 211

Prescriptions, outpatient, 270 Priapism, management by defibrination, 120 Primycin, antibiotic activity, 178

Probenecid, effect on distribution of penicillins, Prochlorperazine, in management of surgical

patients, 62 Propranolol (Inderal - Ayerst), 158; sensitivity to after digoxin intoxication, 90; evaluation in angina pectoris, 121

Protected environments, 212

Pseudomonas, isolations from hospital environ-ment, 178 Pyrogen testing, 286

Quality control, biological preparations, 100 Quinidine-induced hemorrhage, 123

R-49, immunosuppressive action, 61 Rabbit test, for pyrogens, 286 Race, as factor in response to drugs, 14 Redul, see Glycodiazine Refobacin, see Gentamicin Remington Award, Archambault receives, 180 Renal disease, from analgesic abuse, 62 Repoise, see Butaperazine Research, hospital pharmacy, 6, 270, 304; Roche grants for, 32 Reseptyl-urea dressing powder, in urological surgery, 290

Residency programs
Cincinnati VA Hospital, 368
University of Maryland, 180 RhoGAM, see Immune Serum Globulin Rifamycin (Lepetit, Italy), 158 Ritschel, W. A. (author), Therapeutic Incompatibilities Between Penicillins and Other

Antibiotics Administered Simultaneously Ro-4-5282, 230

Roche, research grants, 32 Roentgenography, to determine disintegration time, 278 Roentgenoscopy, to determine disintegration time, 278

Routes of administration, parenteral injections,

16091 R.P., see Metiazinic acid

S

Salicylates anti-inflammatory activity, 30 physiological availability, 278 Salmonella enteritis, exacerbation due to ampicillin, 150 Sandler, Alan I. (co-author), Diffusion of Drugs Through the Cuprophane Membrane, 186 Sch 221, antimicrobial activity, 291 Schizophrenic patients, butaperazine in, 123 Screening test, for pyrogens, 286 Self medication, 270 Serum concentration, 108 Sex as factor in response to drugs, 14 effect of heparin in relation to, 91 Sister M. Gertrude (co-author), A Collabora-tive Program for Clinical Teaching, 38

Sister M. Vera (co-author), A Collaborative Hospital Program for Clinical Teaching, 38

Sjöberg, Bengt, dies, 263

Smith, William E. (author), Clinical Pharmacy, 322 Sobelin, in pediatrics, 291 Society for Advanced Medical Systems, formation, 368 Socioeconomic factors, when prescribing medications, 270 Sodium bicarbonate tablets, disintegration time, 357 Sodium colistimethate, aerosolized, in pulmonary infections, 89 Sodium dicloxacillin monohydrate, (Dynapen-Bristol; Pathocil - Wyeth; Veracillin - Ayerst), Statistics, new drugs, 158 Steroid therapy, intermittent, 179 Streptomycin allergic reaction, 30 efficacy, 312 Sublimaze, see Fentanyl

Slums, lead poisoning in, 333

Succinylcholine injection in pediatrics, 61 urea effect on intraocular tension caused by, 179

Sulfameter (Sulla - Robins), 158 Sulfathiazole tablets, disintegration time, 357 Sulfonamides efficacy, 312 interactions, 130

Sulla, see Sulfameter Surface anesthetics, screening test, 290 Symposium on Formulation Factors Affecting the Therapeutic Performance of Drug Products, summary, 287

T

Tablets, disintegration time, 198, 224, 278, Talwin, see Pentazocine Task Force on Prescription Drugs, 5 Team patient care, 218 Tegretol, see Carbamazepine Teratogenicity, sodium barbital in mice, 333 Testolactone (Squibb), 158 1-H-4,5,6,7-Tetrahydro - 2-benzyl - 1-(mor-pholino-2-aminoethyl) - 4,6 - dimethyl - 5,7-dioxoimidazo (4,5-d) pyrimidine hydrochlo-ride, see AC 3092 Tetrahydrocannabinol, in man, 231 THC, see Tetrahydrocannabinol Therapeutic equivalency, 158, 278, 287 Therapeutic incompatibilities, 355; see also Drug interactions Thorazine, liver damage from, 31 Thorotrast, in cerebral arteriography, 59 Thromboembolic disorders, urobinose in, 58 Thyrotoxicosis, oxyprenalol in, 58 Tioxolonum, cytostatic and antimicrobial activity, 364 Tolbutamide disintegration time, 357 with insulin, hypoglycemic shock, 293 Tolonium, see Toluidine blue Toluidine blue, intoxication from, 367 Tranegyl, in dermatology, 61 Tranquilizer, new, 231 Trichomonacides, interactions, 130 Trimethoprin (B. W., France), 158 Triorthocresylphosphate poisoning, 91 Tuberculosis, diagnostic test, 290

Tuberculostatic drugs, allergic reactions to, 31

UCB 1967, see Dropropizine Unitage, for international standards, 100 University of Cincinnati University of Cincinnatic continuing education seminar, 92, 97 doctor of pharmacy program, 368
University of Maryland, residency program, 180 University of Tennessee, postgraduate training grant, 263 University of Wisconsin, citations to pharmacists, 92 Unlisted Drugs, publishes index of codes for research drugs, 335 Urea, effect on intraocular tension caused by succinylcholine, 179

Uremia, chronic, cephaloridine and cephalothin in, 148
Urinary excretion rate, 108
Urinary germicides, interactions, 130
Urinary 17-ketosteroid determination, interference of nalidixic acid in, 149
Urobinase, in thromboembolic disorders, 58
U.S. Food and Drug Administration, see Food and Drug Administration, see Food

V

Vapor sniffing, dangers, 366
Veracillin, see Sodium dicloxacillin monohydrate
Verapamin, evaluation in angina pectoris, 90
Veterans Administration, pharmacy residencies, 124
Vibration disease, 232
Vibhlastine-induced leukopenia, during late pregnancy, 149
Virginia Hospital Pharmacists' Seminar, 263
Vitamin B-12, malabsorption in patients receiving colchicine, 91
Volume of distribution, defined, 108

W

Wagner, John G. (author)
Biopharmaceutics, 21, 108, 170, 198, 224, 278, 324, 357
Pharmacokinetics, 82, 142, 250
Whitney, Harvey A. K., Jr., appointed at St. Louis College of Pharmacy, 152
Wilhn's tumor, dactinomycin for, 179
World Health Organization, specifications for quality control, 100

X-Y-Z

Zilz, David A. (author), The Pharmacist Utilizes the Patient's Chart, 218

INDEX TO ADVERTISERS

Abbott Laboratories
Normosol-M in D5-W, 2-3, 34-35, 66-67, 94-95, 138-139, 194-195, 248-249
Normosol-R pH 7-4, 166-167, 220-221
Normosol-R pharmaceutical Abstracts, Mr-IFC
Geigy Pharmaceuticals, Division of Geigy Chemical Corp.
Duclolax suppositories, Ja-OBC, Mr-OBC, My-OBC, J-OBC, N-OBC, D-OBC
Intra Products, Division of USV Pharmaceutical Corp.
Dosette syringes, Ja-IFC, F-IFC
Eii Lilly and Company
Identi-Dose, Mr-IBC, Je-IFC, S-IFC, O-IFC, N-IBC, D-IFC
Keflin ampoule, Ja-IBC, F-IBC, Ap-IFC, Ma-IFC, JI-IBC, Ag-IFC, 268, 302, D-IBC
Wm. S. Merrell Company, Division of Richardson-Merrell, Inc.
Cepacol, F-OBC, Ap-OBC, Je-OBC
Parke, Dav's and Company
Chloromycetin, 300-301, 338-339
Paul de Haen, Inc.
Computerized Index: New Drug Analysis, 180, 232, 295, 375
Rachelle Laboratories
Mychel-S, between pages 4 and 5, 46, 75-76, 113-114, 183-184
Roche Laboratories, Division of Hoffmann-LaRoche, Inc.
Roche asks hospital pharmacists about professional services, 16-17, 48-49, 264 and S-IBC
Roche Hospital Pharmacy Information Services, 296 and O-IBC, 336 and N-IBC
Roche welcomes submissions to the 1969
Hospital Pharmacy Research Grant program, 140-141
Tele-E-Dose Librium, 234-235, 266-267, 298-299
Winners of 1968 Hospital Pharmacy Research Grants, 98-99, 154-155
Travenol Laboratories, Ine.
Uromatic System, II-IFC
University of Cincinnati
Applied Biopharmaceutics, continuing education course, 156, Ag-IBC, 236, 340

de Haen

DRUG INFORMATION SYSTEMS

Announce Availability of

COMPUTERIZED INDEX FOR DE HAEN DRUGS IN PROSPECT SYSTEM

Vol. I 1966-1968

Offering access by ten categories to 5300 newly synthesized drugs by chemistry and therapeutic use.

DE HAEN NEW DRUG ANALYSIS

Vol. V 1964-1968

Five year survey of new drug product marketing in the United States with comment on recent trends, description of single chemical entities and listing of ownership of each firm.

.

OTHER DE HAEN SERVICES DE HAEN DRUGS IN RESEARCH

Product information and literature citations with annotations on drugs in the research stage in U.S.

DE HAEN DRUGS IN USE

Clinical drug experience, 6000 reports annually.

ASK FOR DETAILED PROSPECTUS

Paul de Haen, Inc.

11 WEST 42nd STREET NEW YORK, N. Y. 10036
